37169-37-2

Usage

Uses

Used in Pharmaceutical Industry:
N-(tert-butoxycarbonyl)-3,4-dihydroxy-L-Pheny lalanine benzyl ester is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its protective groups facilitate controlled reactions, making it a valuable component in the development of new drugs.
Used in Chemical Research:
In the field of chemical research, N-(tert-butoxycarbonyl)-3,4-dihydroxy-L-Pheny lalanine benzyl ester is employed as a model compound for studying the reactivity and properties of amino acids and their derivatives. Its complex structure allows researchers to explore the effects of protective groups on the chemical behavior of molecules.
Used in Biochemistry:
N-(tert-butoxycarbonyl)-3,4-dihydroxy-L-Pheny lalanine benzyl ester is used as a research tool in biochemistry to investigate the role of amino acids in protein structure and function. Its protective groups can be selectively removed to study the effects on protein folding and stability.

Upstream product

• 59-92-7 levodopa 
• 24424-99-5 di-tert-butyl dicarbonate 
• 100-39-0 benzyl bromide 
• 30033-24-0 (2S)-3-(3,4-dihydroxyphenyl)-2-[(tert-butoxy)carbonylamino]propanoic acid 
• 55720-47-3 3,4-dihydroxy-L-phenylalanine benzyl ester 

Downstream Products

• 1379614-09-1 (2S)-2-amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid tosylate 
• 1379613-67-8 (2S)-3-((3,4-bis((2-benzoyloxy)-2-methylpropanoyl)oxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid 
• 1379614-08-0 (2S)-2-amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid 
• 1379613-68-9 (2S)-2-amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid hydrochloride 
• 1379613-66-7 (2S)-((4-(3-benzyloxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl-1,2-phenylene)bis(oxy))bis(2-methyl-1-oxopropan-2,1-diyl)dibenzoate 
• 130962-23-1 (S)-benzyl 3-(3,4-bis-benzyloxyphenyl)-2-(tert-butoxycarbonylamino)propanoate 

Relevant academic research and scientific papers

Carbidopa and L-Dopa Prodrugs and Methods of Use

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising admini

NOVEL COMPOUND AND MEDICAL USE THEREOF

Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)p